P25.01 Efficacy of Weekly Paclitaxel-Bevacizumab Combination in Advanced NSCLC: AVATAX, A Retrospective Multicentric Study

Bilger, G.; Toffart, A.C.; Darrason, Marie; Duruisseaux, M.; Ulmer, Lucie; Wang, P.; Leprieur, Étienne Giroux; Girard, Nicolas; Massiani, Marie-Ange; Bore, Paul; Descourt, R.; Pinsolle, J.; Valery, Solene; Monnet, I.; Swalduz, Aurélie; Tissot, Claire; Fournel, P.; Baranzelli, A.; Cortot, A.; Decroisette, C.

doi:10.1016/j.jtho.2021.08.380

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the Taxane/ICI combination therapy has been already tested in clinic and appears to result in beneficial effects (29,30,37,38). Nevertheless, based on our findings, we would like to propose that the combination therapy may require further testing in terms of Taxane dosing and scheduling relatively to the ICI treatment in clinical trials to further improve clinical benefit (33)(34)(35)39).…”

Section: Discussionmentioning

confidence: 91%

cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel

Serpico

Pisauro²,

Grieco³

2023

Front. Immunol.

View full text Add to dashboard Cite

Taxanes are Microtubule-Targeting Agents (MTAs) that exert potent anticancer activity by directly killing cancer cells. However, recent evidence suggests that they may also stimulate inflammation and anticancer adaptive immunity and that these actions strongly contribute to their therapeutic efficacy. Details on how Taxanes may modulate inflammation and anticancer immunity are, nevertheless, still missing. We show here that at very low doses the Taxane Paclitaxel (Pxl) indeed induces a potent proinflammatory response in various cancer cell types in a cyclic GMP-AMP (cGAMP) synthase (cGAS)- and Stimulator of Interferon Genes (STING)-dependent manner, leading to interferon (IFN) signaling. However, we find that Pxl treatment also strongly upregulates the expression of the immune checkpoint protein Programmed Death-Ligand 1 (PD-L1) in cancer cells, therefore, inducing an inhibitory response to adaptive immunity potentially attenuating anticancer immunity and therapeutic success. These observations provide a mechanistic explanation of why clinical benefit may derive from the combination of Pxl with Immune Checkpoint Inhibitors (ICIs) and suggest that more accurately tailoring dosage and schedule of this combination therapy may provide benefit in the management of a larger number of cancer types and stages.

show abstract